Le Lézard
Classified in: Science and technology, Covid-19 virus
Subjects: CPN, AVO

Historic Media/Politics/Issues Conference


CHARLOTTE, N.C., Oct. 12, 2020 /PRNewswire-PRWeb/ -- The historic media/politics/issues conference "20 Days To Save The USA" will commence Oct. 15 and continue through Election Day, Nov. 3.

Event organizer Jerry McGlothlin, founder of Special Guests, an issues-oriented political celebrity publicity agency, says this virtual conference and convention features 80 exhibitors, 100 speakers, and 120 hours of online and live content weekdays from 6:00 pm-11:00 pm Eastern Time with full day and nighttime programming on weekends.

Conference speakers will issue clarion calls for U.S. citizens to take back the USA from the usurpers of liberty, obsessed with overthrowing our Republic and replacing it with Socialism. Seminar topics include right to bear arms, border security, limited government, right to life, anarchy in Democratic Downtowns, Cancel Culture, and Covid-19.

AMONG SPEAKERS: Lt. General William "Jerry" Boykins (U.S. Army ret.), Political Analyst Dick Morris, Lt. Col. Robert Maginnis (U.S. Army ret.), Activist Mommy Elizabeth Johnston, Former Nebraska Attorney General Don Stenberg who fought the landmark Supreme Court fight against partial birth, Stephen Willeford, who stopped most deadly church shooting in the history of Texas, AOC Congressional opponent John Cummins, Trump Military High School classmate Peter Ticktin, White House insider Mike McCormick, and Roger Stone, and Psychiatrist Carole Lieberman who analyzes Biden's mental state and Trump's Covid-impacted debate performance.

Event registration is at: SpecialGuests.com

Sneak peek #1: https://vimeo.com/463956579/

Sneak peek #2: https://vimeo.com/466671475/

REGISTER AND DOWNLOAD THE WHOVA APP FOR FULL ACCESS TO SPEAKERS, NETWORKING, ROUNDTABLE DISCUSSIONS, EXHIBIT BOOTHS, AND MORE!

App for PC: https://whova.com/portal/webapp/dtsu_202010/
App for Smart Phones: Download Link allows you to interact with others on your phone in the app more conveniently wherever you go.

Contact: Rachel Ford [email protected] or Jerry McGlothlin 919-437-0001 to schedule an interview.

 

SOURCE Special Guests


These press releases may also interest you

at 07:45
Latigo Biotherapeutics Appoints Tim Lugo as Chief Financial Officer and Adds Beth Seidenberg and Jim Tananbaum to Board of Directors
Latigo Biotherapeutics Inc. ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that...

at 07:42
Jumptuit Introduces Global Sensory Intelligence (GSI) to Reduce Geopolitical and Environmental Event Risk
Jumptuit is pleased to announce the activation of its Global Sensory Intelligence (GSI) providing simultaneous observation of atmospheric, terrestrial, and oceanic conditions, and human activity and artificial systems....

at 07:40
4M Therapeutics Announces Positive Preclinical Data for Lead Asset 4MT2001 Demonstrating Central Nervous System Target Engagement
4M Therapeutics Inc. (4MTx), an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative diseases, today announced new preclinical data for its lead program, 4MT2001, a novel small molecule glycogen synthase...

at 07:35
Mobileye to End Internal Lidar Development
Mobileye has chosen to end the internal development of next-generation frequency modulated continuous wave (FMCW) lidars for use in autonomous and highly automated driving systems. As part of our regular review of the long-term technology roadmap,...

at 07:35
SelectQuote to Release Fiscal Fourth Quarter and Full Year 2024 Earnings on September 13
SelectQuote, Inc. , a leading distributor of Medicare insurance policies and owner of an emerging Healthcare Services platform, today announced it will release its fourth quarter and full year 2024 financial results before market open on Friday,...

at 07:35
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb® programs in development for the treatment of patients with autoimmune...

More news about Science and technology...


News published on and distributed by: